Prime Medicine, Inc. (PRME) Financial Statements
Prime Medicine, Inc. (PRME) reported trailing twelve-month revenue of $4.1M (down 17.9% year on year) and net income of -$187.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$156.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRMEPrime Medicine, Inc.Follow PRME — free
—
Price chart with a free account
- Market cap
- 665.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 3.0 | 4.6 | 4.1 | |
| Research & development | 155.3 | 160.6 | 146.2 | |
| Operating income | -202.5 | -208.4 | -196.5 | |
| Pre-tax income | -195.9 | -201.1 | -187.9 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -195.9 | -201.1 | -187.9 | |
| Diluted EPS ($) | -1.65 | -1.35 | -1.07 | |
| Diluted shares (mn) | 118.6 | 148.8 | — |
USD millions · SEC XBRL
Prime Medicine, Inc. — questions
- What is Prime Medicine, Inc.'s revenue?
- $4.1M over the twelve months to 2026-06-30, down 17.9% year on year, from its 10-Q and 10-K filings.
- What is Prime Medicine, Inc.'s net income?
- -$187.9M over the twelve months to 2026-06-30.
- What is Prime Medicine, Inc.'s free cash flow?
- -$156.8M over the twelve months to 2026-06-30.
- What are Prime Medicine, Inc.'s diluted earnings per share?
- $-1.07 over the twelve months to 2026-06-30.
Every figure on this page comes from Prime Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.